Outcomes by occurrence of immune-mediated adverse events with tremelimumab plus duralumab in the Phase 3 HIMALAYA study in unresctable hepatocellar carsinoma

Outcomes by occurrence of immune-mediated adverse events with tremelimumab plus duralumab in the Phase 3 HIMALAYA study in unresctable hepatocellar carsinoma.